SCHEMBL5633176

SCHEMBL5633176

CCOC(Cc1ccc(SCC=CC#Cc2ccc(-c3ccc(-c4ccc(C#CC=CCSc5ccc(OCC(=O)O)c(C)c5)cc4)cc3)cc2)cc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 20/20 0.65
PPARA Q07869 14/20 0.65
PPARG P37231 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5634249 1.00 PPARD (0.65) PPARDPPARAPPARG
SCHEMBL5634252 1.00 PPARD (0.65) PPARDPPARAPPARG
SCHEMBL5634104 0.98 PPARD (0.68) PPARDPPARAPPARG
SCHEMBL5634106 0.98 PPARD (0.68) PPARDPPARAPPARG
SCHEMBL5633844 0.95 PPARA (0.66) PPARDPPARAPPARG
SCHEMBL5633654 0.95 PPARA (0.66) PPARDPPARAPPARG
SCHEMBL5633842 0.95 PPARA (0.66) PPARDPPARAPPARG
SCHEMBL5633983 0.92 PPARA (0.69) PPARDPPARAPPARG
SCHEMBL5633976 0.92 PPARA (0.69) PPARDPPARAPPARG
SCHEMBL5632416 0.92 PPARD (0.67) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438283-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE NOVO NORDISK A/S (DK) 2004-07-21 EP claimed
US-20030109579-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2003-06-12 US claimed
WO-2003033453-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE NOVO NORDISK A/S (DK) 2003-04-24 WO claimed
US-7220877-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2007-05-22 US disclosed
US-20030109579-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2003-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109579-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD PPARD 3/4885PPARA 2/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.